DISCIPLE phase III: a “stop and go” strategy
First-line immunotherapy is a well-established treatment approach for patients with advanced non-small-cell lung cancer (NSCLC) who do not possess targetable mutations. However, the conventional practice of administering immunotherapy for a duration of 2 years lacks indisputable evidence. Is it possible that an alternative “stop and go” strategy, involving a 6-month induction period of dual immunotherapy with Nivolumab + Ipilimumab, followed by observation in patients with disease control, could be non-inferior to continuous immunotherapy until disease progression or unacceptable toxicity?
The DICIPLE phase III study, which tested the alternative “stop and go” strategy in advanced NSCLC patients, was conducted at multiple hospitals across France. Prof. Dr. Anne-Claire Toffart, a co-author of the study, provided extensive insights on the results from this multicenter trial in an interview with MediMix.
With the educational support of:
